Sign In
Buy MRTX
$58.70
+0 (+0%)
At Close: Apr 19, 2024
Mirati Therapeutics, Inc. (MRTX) CEO David Meek on Q4 2021 Results - Earnings Call Transcript
10:01pm, Monday, 28'th Feb 2022
Mirati Therapeutics, Inc. (MRTX) CEO David Meek on Q4 2021 Results - Earnings Call Transcript
Mirati Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
09:16pm, Monday, 28'th Feb 2022 Seeking Alpha
Mirati Therapeutics GAAP EPS of -$3.72 misses by $0.79
09:08pm, Monday, 28'th Feb 2022 Seeking Alpha
Mirati Therapeutics press release (MRTX): Q4 GAAP EPS of -$3.72 misses by $0.79.Approx $1.5 billion in cash, cash equivalents, and short-term investments.
Mirati Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates
09:01pm, Monday, 28'th Feb 2022 PR Newswire
SAN DIEGO, Feb. 28, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full year 2021 and recent corporate updates. "Mirati is aggressively advancing its mission for…
Mirati Therapeutics Q4 2021 Earnings Preview (NASDAQ:MRTX)
10:35pm, Sunday, 27'th Feb 2022 Seeking Alpha
Mirati Therapeutics (NASDAQ:MRTX) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$3.01 (-44.7% Y/Y) and…
Is a Surprise Coming for Mirati (MRTX) This Earnings Season?
01:34pm, Friday, 25'th Feb 2022 Zacks Investment Research
Mirati (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Surprise Coming for Mirati (MRTX) This Earnings Season?
09:59am, Friday, 25'th Feb 2022
Mirati (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates
12:55pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.
5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates
09:15am, Thursday, 24'th Feb 2022
Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.
Mirati (MRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
08:00pm, Monday, 21'st Feb 2022 Zacks Investment Research
Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirati (MRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
04:11pm, Monday, 21'st Feb 2022
Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirati (MRTX) Down on Longer Review Period for Adagrasib NDA
04:55pm, Thursday, 17'th Feb 2022 Zacks Investment Research
The FDA accepts Mirati's (MRTX) NDA for its lung cancer candidate, adagrasib. A decision is expected by Dec 14, 2022.
Mirati (MRTX) Down on Longer Review Period for Adagrasib NDA
01:05pm, Thursday, 17'th Feb 2022
The FDA accepts Mirati's (MRTX) NDA for its lung cancer candidate, adagrasib. A decision is expected by Dec 14, 2022.
Biotech Stock Values Cut in Half While New Drug Setbacks Pile Up - BNN Bloomberg
08:04pm, Wednesday, 16'th Feb 2022 BNN Bloomberg
(Bloomberg) -- Former high flying biotechnology favorites Mirati Therapeutics Inc. and Sage Therapeutics Inc. have lost more than half their value from record highs, hurt by growing pessimism on new medicines as well as the higher rate environment damaging most stocks.
Why Mirati Therapeutics Stock Is Plunging Today
07:24pm, Wednesday, 16'th Feb 2022 The Motley Fool
A longer-than-expected regulatory review for the company's lung cancer drug is weighing on its shares today.
